Markers of Chlamydia pneumoniae and human cytomegalovirus infection in patients with chronic peripheral vascular disease and their relation to inflammation, endothelial dysfunction and changes in lipid metabolism
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- arteria femoralis diagnostické zobrazování metabolismus mikrobiologie patologie virologie MeSH
- arteria poplitea diagnostické zobrazování metabolismus mikrobiologie patologie virologie MeSH
- ateroskleróza diagnostické zobrazování etiologie metabolismus mikrobiologie patofyziologie virologie MeSH
- bérec krevní zásobení MeSH
- biologické markery MeSH
- cévní endotel patofyziologie MeSH
- Chlamydophila pneumoniae izolace a purifikace MeSH
- cytokiny krev MeSH
- cytomegalovirové infekce komplikace metabolismus patofyziologie virologie MeSH
- DNA bakterií analýza krev MeSH
- DNA virů analýza krev MeSH
- dospělí MeSH
- dyslipidemie etiologie MeSH
- infekce bakteriemi rodu Chlamydophila komplikace metabolismus mikrobiologie patofyziologie MeSH
- ischemie etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipoprotein (a) krev MeSH
- mladý dospělý MeSH
- onemocnění periferních cév diagnostické zobrazování etiologie metabolismus mikrobiologie patofyziologie virologie MeSH
- radiografie MeSH
- senioři MeSH
- stenóza MeSH
- vaskulitida etiologie metabolismus mikrobiologie patofyziologie virologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- cytokiny MeSH
- DNA bakterií MeSH
- DNA virů MeSH
- lipoprotein (a) MeSH
Our aim was to detect markers of Chlamydia pneumoniae (CPN) and human cytomegalovirus (HCMV) infection in patients with peripheral vascular occlusive disease and to follow markers of inflammation, endothelial dysfunction and lipid metabolism alteration in patients with active infection. CPN genome was detected in 9 (47.4 %) patients by at least one PCR method. Serological markers of acute CPN infection were found in 5 (26.3 %) subjects; each of them showed also positivity in at least one of the PCR methods. HCMV DNA were detected in 2 (10.5 %) patients; HCMV-specific antibodies were detected in 14 (73.7 %) subjects, however only in IgG subclass. Subjects with HCMV PCR positivity thus showed no serological markers of active HCMV infection. Laboratory findings of acute CPN infection were associated with increased plasma levels of Lp(a), triacylglycerols, atherogenic index of plasma and E-selectin (p < 0.05). No significant differences were found in the other markers, including plasma levels of total cholesterol, ferritin, homocysteine, oxidized LDL, IL-6, IL-8, IL-18, TNF-alpha, soluble forms of VCAM-1 and ICAM-1, von Willebrand factor, C-reactive protein, and plasma nitrites & nitrates. Frequent presence of chlamydial DNA in atheromatous plaques from patients with peripheral vascular disease was confirmed. HCMV DNA was detected only sporadically and with positivity in anamnestic anti-HCMV antibodies (IgG) only, indicating a rare presence of latent virus rather than active replication. Patients with laboratory markers of acute CPN infection exhibited more pronounced alterations in lipid metabolism and endothelial dysfunction.
Zobrazit více v PubMed
J Vasc Surg. 1997 Jul;26(1):29-31 PubMed
Atherosclerosis. 1981 Jan-Feb;38(1-2):51-61 PubMed
Haematologica. 2005 Jan;90(1):94-9 PubMed
Arctic Med Res. 1988;47 Suppl 1:458-61 PubMed
Radiology. 2000 Nov;217(2):587-92 PubMed
J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9 PubMed
Clin Microbiol Infect. 2002 Oct;8(10):654-61 PubMed
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2910-3 PubMed
J Infect Dis. 2000 Jun;181 Suppl 3:S402-10 PubMed
J Gen Virol. 1993 Dec;74 ( Pt 12):2699-707 PubMed
Int Heart J. 2006 Jul;47(4):511-9 PubMed
Eur Heart J. 2000 Apr;21(8):639-46 PubMed
JAMA. 1986 Nov 14;256(18):2540-4 PubMed
J Infect Dis. 1995 Aug;172(2):585-8 PubMed
Clin Biochem. 2001 Oct;34(7):583-8 PubMed
J Clin Pathol. 1993 Apr;46(4):313-7 PubMed
Eur Cytokine Netw. 2006 Mar;17(1):4-12 PubMed
J Infect Dis. 2000 Jun;181 Suppl 3:S432-6 PubMed
Ann Intern Med. 1996 Dec 15;125(12):979-82 PubMed
S Afr Med J. 1992 Sep;82(3):158-61 PubMed
J Clin Microbiol. 2001 Feb;39(2):519-24 PubMed
Circulation. 1998 Aug 18;98(7):628-33 PubMed
Am J Pathol. 1997 May;150(5):1785-90 PubMed
J Clin Microbiol. 2004 Sep;42(9):3937-41 PubMed
Clin Infect Dis. 2001 Aug 15;33(4):492-503 PubMed
J Lipid Res. 2004 May;45(5):873-80 PubMed
Lancet. 1997 Aug 9;350(9075):430-6 PubMed
J Infect Dis. 2003 Oct 15;188(8):1085-93 PubMed
J Infect Dis. 1993 Apr;167(4):841-9 PubMed
J Clin Virol. 2005 Jan;32(1):29-32 PubMed
J Clin Microbiol. 2003 Apr;41(4):1454-7 PubMed
Arterioscler Thromb. 1993 Oct;13(10):1501-4 PubMed
Microb Pathog. 1996 Nov;21(5):407-11 PubMed
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6911-4 PubMed
J Clin Microbiol. 2002 Dec;40(12):4428-34 PubMed
Diabetes Care. 1998 Dec;21(12):2191-2 PubMed
